- Home
- SHOT vs FEMY Comparison
SHOT vs FEMY Comparison
Compare SHOT & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- FEMY
- Stock Information
- Founded
- SHOT 2018
- FEMY 2004
- Country
- SHOT United States
- FEMY United States
- Employees
- SHOT N/A
- FEMY N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- FEMY Medical/Dental Instruments
- Sector
- SHOT Health Care
- FEMY Health Care
- Exchange
- SHOT Nasdaq
- FEMY Nasdaq
- Market Cap
- SHOT 30.4M
- FEMY 31.9M
- IPO Year
- SHOT 2020
- FEMY 2021
- Fundamental
- Price
- SHOT $0.43
- FEMY $0.91
- Analyst Decision
- SHOT
- FEMY Strong Buy
- Analyst Count
- SHOT 0
- FEMY 3
- Target Price
- SHOT N/A
- FEMY $8.67
- AVG Volume (30 Days)
- SHOT 6.3M
- FEMY 282.0K
- Earning Date
- SHOT 08-13-2025
- FEMY 08-07-2025
- Dividend Yield
- SHOT N/A
- FEMY N/A
- EPS Growth
- SHOT N/A
- FEMY N/A
- EPS
- SHOT N/A
- FEMY N/A
- Revenue
- SHOT $573,336.00
- FEMY $1,699,232.00
- Revenue This Year
- SHOT N/A
- FEMY $231.84
- Revenue Next Year
- SHOT N/A
- FEMY $245.28
- P/E Ratio
- SHOT N/A
- FEMY N/A
- Revenue Growth
- SHOT 69.32
- FEMY 61.97
- 52 Week Low
- SHOT $0.23
- FEMY $0.69
- 52 Week High
- SHOT $1.77
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- SHOT 54.76
- FEMY 50.88
- Support Level
- SHOT $0.35
- FEMY $0.90
- Resistance Level
- SHOT $0.48
- FEMY $0.99
- Average True Range (ATR)
- SHOT 0.06
- FEMY 0.07
- MACD
- SHOT 0.01
- FEMY 0.01
- Stochastic Oscillator
- SHOT 46.94
- FEMY 39.48
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.